# Connect® MM- The Multiple Myeloma Disease Registry

> **NCT01081028** · — · TERMINATED · sponsor: **Celgene** · enrollment: 3011 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** First-line therapy
- **DRUG:** Second-line Multiple Myeloma treatments

## Key facts

- **NCT ID:** NCT01081028
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 3011 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081028, "Connect® MM- The Multiple Myeloma Disease Registry". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01081028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*